X-Chem, Pfizer Collaborate on Screening for Inflammatory, Orphan Diseases | GenomeWeb

NEW YORK (GenomeWeb) – Biotech firm X-Chem today announced a multi-target collaboration with Pfizer for the potential development of new treatments for inflammatory and orphan diseases.

X-Chem will apply its discovery engine to identify new leads for several of Pfizer's treatment development programs. Pfizer has an exclusive option to license compounds generated from the collaboration. Further details of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.